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ABSTRACT
Cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6) reactivation after transplan-
tation put patients at an increased risk of graft rejection mainly among those who receive
organs that are positive in their donor biopsies. The aim of this study was to investigate the
presence of CMV and HHV-6 DNA in liver biopsy specimens from the donors and from
their grafts for correlation with rejection after transplantation. We followed 41 liver
transplantation patients whose samples were evaluated using nested-polymerase chain
reactions (N-PCR). Twenty-one (51%) of the 41 studied patients experienced rejection;
4/21 (19%) were CMV positive in the donor biopsy specimens and remained positive;
another 5 subjects became positive. The patients who received organs from donors with
biopsies positive for CMV demonstrated a trend to develop graft rejection after trans-
plantation (Fisher’s exact test [P  .0591] with significant results on univariate and
multivariate analysis [P  .042]). Eight of the 21 who experienced rejection episodes were
HHV-6 positive in the donor biopsy but there was no statistical significance CMV DNA
diagnosed in liver donor biopsies remained positive posttransplantation in liver biopsy
recipients; it was considered a tendency to develop acute cellular rejection after
transplantation.
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pHERPESVIRUS reactivation is common after livertransplantation. A seropositive donor coupled with a
seronegative recipient is a risk factor for primary cytomeg-
alovirus (CMV) infection. Secondary infection by reactiva-
tion or superinfection may also lead to CMV disease during
immunosuppression. Among recipients who receive immu-
nosuppressive medications there is a seroprevalence of
human herpesvirus-6 (HHV-6), which reactivates from la-
tency posttransplantation, often together with CMV infec-
tion.1 CMV and HHV-6 establish latent infections for the
ifetime of the host with possible reactivation later.2 Among
the factors associated with virus reactivation after liver
transplantation is acute allograft rejection.3,4 Our study
nalyzed the presence of CMV and HHV-6 DNA in donor
iver biopsy specimens correlated with rejection episodes
fter transplantation.
PATIENTS AND METHODS
Herpesvirus was studied prospectively in 41 liver transplantation
patients from 2005 to 2007 in an epidemiological, observational,
analytic, longitudinal cohort prospective study. Recipient monitor-
ing started at the moment of surgery. The first liver biopsy
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Transplantation Proceedings, 44, 2441–2444 (2012)specimen was collected at the bench from the organ before
transplantation (pretransplantation graft biopsy). Other liver bi-
opsy specimens (posttransplantation) were collected when clini-
cally indicated due to elevated liver enzyme levels. Among 145
biopsy specimens: 41 were from the donor and 104 from the graft.
We analyzed the biopsy specimens using nested-polymerase chain
reaction (N-PCR) for CMV and HHV-6 DNA as well as monitored
the recipients for cellular rejection. The diagnostic and clinical
monitoring of graft function for acute rejection episodes were
evaluated according to the Banff International Consensus.5 All
cute rejection episodes were treated with methylprednisolone
ccording to our protocol. All patients from this study received
rophylaxis for Herpes simplex infection.6
All recipients were positive for CMV immunoglobulin G (IgG)
before transplantation; no recipient showed positive serology for
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2442 GUARDIA-SILVA, STUCCHI, SAMPAIO, ET ALHHV-6 before transplantation. All donors were CMV positive
serologically. All patients underwent our previously published
protocol for immunosuppression.6
Molecular Tissue Testing
Viral DNA was extracted from liver biopsy specimens using the
Quiagen Dneasy Tissue Kit (Uniscience, São Paulo, Brazil) accord-
ing to the manufacturer’s instructions with some modifications to
achieve final elution volumes of 30 L.6
CMV and HHV-6 N-PCR Amplification
Five microliters of extracted DNA were used for the N-PCR for
CMV and HHV-6 using a mixture containing specific primers
(CMV primers; Invitrogen, São Paulo, Brazil), using the a previ-
ously described technique7 with some modifications. Specific prim-
ers for HHV-6 (HHV-6 primers; Invitrogen) were applied with the
technique previously described by Secchiero et al8 with some
modifications. The amplifications were performed in a Peltier
Thermal Cycler (MJ Research, Waltham, Mass, United States).
The N-PCR products were analyzed under UV light after electro-
phoresis in agarose gels (Gibco-BRL Life Technology, Carlsbad,
California, United States) in tetramethylbenzidine buffer after
staining with ethidium bromide. All primer sequences and PCR
products were analyzed using the Genbank database before initi-
ating the study. PCR using primers for beta-globin gene amplifi-
cation, which were performed on samples to detect possible
false-negative results, were not included in this study.
Statistical Analysis
The results were compared with chi-square and Fisher exact test
and when necessary with univariate or multivariate logistic analy-
ses. For all tests, P  .05 was considered statistically significant.
his study was approved by our Institutional Ethics Committee
number 030/2006).
RESULTS
Twenty-one (51%) of 41 studied patients showed positive
histopathology for liver rejection; 4/21 (19%) were positive
for CMV in the pretransplantation graft biopsy and re-
mained positive, whereas another 5 became positive on
posttransplant graft biopsies (Table 1). The patients who
displayed a pretransplantation graft biopsy positive for
CMV DNA show significant results (P  .042) upon
nivariate or multivariate analysis (Table 2), as well as in
isher exact test (Table 3), with a tendency toward devel-
pment of graft rejection after transplantation (P  .0591).
ight of the 21 who were positive for HHV-6 on pretrans-
lantation graft biopsies had rejection but it was not
ignificant. The other patients who did not have rejection
nd were positive for herpesvirus are described in Tables 3
nd 4.
DISCUSSION
The beta-herpesviruses are common viral pathogens that
influence the outcomes of liver transplantation. Their ef-
fects are associated with an increased predisposition to
rejection reducing allograft survival. Fifty-one percent ofatients in this study developed graft rejection and 71%
isplayed herpesvirus infection. Allograft rejection is the
ost potent inducer of CMV reactivation, and thus is
onsidered a significant risk factor for CMV disease after
iver transplantation. A few previous studies4,9,10 have
eported an association between HHV-6 and allograft
ysfunction or rejection.
A recent study showed CMV positivity (CMV-IgG) among
4.7% of patients before transplantation, hence there is some
mportance of serological investigations and diagnostic exam-
nations before transplantation.11 CMV-seronegative recipi-
ents of liver allografts from CMV-seropositive donors
(CMVD/R) are at the highest risk of CMV disease and its
omplications.12 In our analysis the patients who displayed
positive CMV DNA in pretransplantation graft biopsies were
significantly more likely to develop rejection episodes after
transplantation (Table 2).
Almost all patients who had CMV DNA in the donor
biopsy remained positive after transplantation and had
rejection. After transplantation 14 recipients were positive
Table 1. Patients’ Demographic Data According to ACR
Presence or Not (no ACR)
Variables
ACR
(n  21)
No ACR
(n  20)
Donor data
Gender
Male 14 (66.6%) 16 (80.0%)
Female 7 (33.4%) 4 (20.0%)
Age (y) 29.2  11.8 26.8  9.8
Brain death cause
Trauma 13 (61.9%) 13 (65.0%)
CVA 6 (28.6%) 3 (15.0%)
Others 2 (9.5%) 4 (20.0%)
N-PCR/CMV
Positive 4 (19.0%) 0
Negative 17 (81.0%) 20 (100.0%)
N-PCR/HHV-6
Positive 8 (38.1%) 7 (35.0%)
Negative 13 (61.9%) 13 (65.0%)
Recipient data
Gender
Male 16 (76.2%) 16 (80.0%)
Female 5 (23.8%) 4 (20.0%)
Age (y) 46.1  13.9 43.6  12.1
Biopsies (n) 2.5  1.1 2.6  1.7
Rejection time (d) 143.6  176.1
Hepatitis C
Positive 14 (66.6%) 12 (60.0%)
Negative 7 (33.4%) 8 (40.0%)
Cold ischemia (min) 699.4  210.3 731.5  175.1
N-PCR/CMV
Positive 9 (42.8%) 4 (20%)
Negative 12 (57.2%) 16 (80.0%)
N-PCR/HHV-6
Positive 12 (57.2%) 10 (50.0%)
Negative 9 (42.8%) 10 (50.0%)
Abbreviations: ACR, acute cellular rejection; CVA, cerebrovascular accident.for CMV DNA, 9 had rejection as shown in Table 2
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CMV AND HHV-6 2443Razonable et al demonstrated a significant association
between acute rejection and delayed-onset CMV disease in
liver transplant recipients. CMV disease caused significant
morbidity and reduced allograft survival.4,9,13
Of 21 recipients who experienced rejection, HHV-6
DNA was observed in 8 pretransplantation graft biopsy
specimens and 6/8 remained positive after transplantation;
another 6 became positive after transplantation. Although
HHV-6 showed a higher positivity than CMV, we failed to
observe a significant relation although other studies have
suggested that HHV-6 causes dysfunction that can lead to
rejection after transplantation.2,14
In summary CMV DNA diagnosed in pretransplantation
graft biopsy specimens remained positive posttransplanta-
tion on graft biopsies. This common complication nega-
Table 2. Univariate and Multivariate
Variable* Category
HHV-5 donor† Negative
Positive
HV-5 recipient Negative
Yes
HV-6 donor Negative
Positive
HV-6 recipient Negative
Yes
o-infection No
Yes
ime of detection (d) Continuous variable (100 d)
o. of biopsies Continuous variable
ge Continuous variable
ender Female
Male
iver disease Others
HCV
onor age Continuous variable
onor gender Female
Male
onor death Others
Trauma
old ischemia Continuous variable
Abbreviations: OR, odds ratio; CI, confidence interval.
*CI 95%  confidence Interval 95% of OR.
†After stepwise using multivariate analysis.
Table 3. Comparison of CMV and HHV-6 Infection According
to Pretransplantation and Posttransplantation Biopsies and
Presence of ACR Observed in the Recipients
Pretransplantation Graft
Biopsies (41)
Posttransplantation Graft
Biopsies (41)
CMV ACR (21) No ACR (20) ACR (21) No ACR (20)
Positive 4* 0 9 5
Negative 17 20 12 15
HHV-6 ACR (21) No ACR (20) ACR (21) No ACR (20)
Positive 8 7 12 10
Negative 13 13 9 10*Fisher exact test (P  .0591).ively influences liver transplantation outcomes and is a risk
actor to develop acute cellular rejection episodes.
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